|Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease|
OMA El-Agnaf, SA Salem, KE Paleologou, MD Curran, MJ Gibson, ...
The FASEB journal 20 (3), 419-425, 2006
|Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium|
IG McKeith, BF Boeve, DW Dickson, G Halliday, JP Taylor, D Weintraub, ...
Neurology 89 (1), 88-100, 2017
|α-Synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including human plasma|
OMA El-Agnaf, SA Salem, KE Paleologou, LJ Cooper, NJ Fullwood, ...
The FASEB Journal 17 (13), 1945-1947, 2003
|Protein aggregation in the brain: the molecular basis for Alzheimer’s and Parkinson’s diseases|
GB Irvine, OM El-Agnaf, GM Shankar, DM Walsh
Molecular medicine 14 (7-8), 451-464, 2008
|Aggregates from mutant and wild‐type α‐synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β‐sheet and amyloid‐likeá…|
OMA El-Agnaf, R Jakes, MD Curran, D Middleton, R Ingenito, E Bianchi, ...
FEBS letters 440 (1-2), 71-75, 1998
|Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease|
T Tokuda, MM Qureshi, MT Ardah, S Varghese, SAS Shehab, T Kasai, ...
Neurology 75 (20), 1766-1770, 2010
|α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer|
B Fauvet, MK Mbefo, MB Fares, C Desobry, S Michael, MT Ardah, E Tsika, ...
Journal of Biological Chemistry 287 (19), 15345-15364, 2012
|Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease|
T Tokuda, SA Salem, D Allsop, T Mizuno, M Nakagawa, MM Qureshi, ...
Biochemical and biophysical research communications 349 (1), 162-166, 2006
|Certain inhibitors of synthetic amyloid β-peptide (Aβ) fibrillogenesis block oligomerization of natural Aβ and thereby rescue long-term potentiation|
DM Walsh, M Townsend, MB Podlisny, GM Shankar, JV Fadeeva, ...
Journal of Neuroscience 25 (10), 2455-2462, 2005
|Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration|
B Mollenhauer, V Cullen, I Kahn, B Krastins, TF Outeiro, I Pepivani, J Ng, ...
Experimental neurology 213 (2), 315-325, 2008
|Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α‐synuclein protein implicated in Parkinson's disease|
OMA El-Agnaf, R Jakes, MD Curran, A Wallace
FEBS letters 440 (1-2), 67-70, 1998
|Formation of hydrogen peroxide and hydroxyl radicals from Aβ and α-synuclein as a possible mechanism of cell death in Alzheimer’s disease and Parkinson’s disease|
BJ Tabner, S Turnbull, OMA El-Agnaf, D Allsop
Free Radical Biology and Medicine 32 (11), 1076-1083, 2002
|Court JA, Schlossmacher MG, Allsop D (2006) Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease|
OM El-Agnaf, SA Salem, KE Paleologou, MD Curran, MJ Gibson
Faseb j 20 (3), 419-425, 0
|Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia|
BJ Tabner, OMA El-Agnaf, S Turnbull, MJ German, KE Paleologou, ...
Journal of Biological Chemistry 280 (43), 35789-35792, 2005
|α-Synuclein implicated in Parkinson’s disease catalyses the formation of hydrogen peroxide in vitro|
S Turnbull, BJ Tabner, OMA El-Agnaf, S Moore, Y Davies, D Allsop
Free Radical Biology and Medicine 30 (10), 1163-1170, 2001
|Oligomerization and toxicity of β-amyloid-42 implicated in Alzheimer's disease|
OMA El-Agnaf, DS Mahil, BP Patel, BM Austen
Biochemical and biophysical research communications 273 (3), 1003-1007, 2000
|γ-Synuclein and the progression of cancer|
M Ahmad, S Attoub, MN Singh, FL Martin, OMA El-Agnaf
The FASEB Journal 21 (13), 3419-3430, 2007
|Aggregation and neurotoxicity of α-synuclein and related peptides|
OMA EI-Agnaf, GB Irvine
Biochemical Society Transactions 30 (4), 559-565, 2002
|Detection of elevated levels of soluble α-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies|
KE Paleologou, CL Kragh, DMA Mann, SA Salem, R Al-Shami, D Allsop, ...
Brain 132 (4), 1093-1101, 2009
|A strategy for designing inhibitors of α-synuclein aggregation and toxicity as a novel treatment for Parkinson’s disease and related disorders|
OMA El-Agnaf, KE Paleologou, B Greer, AM Abogrein, JE King, SA Salem, ...
The FASEB journal 18 (11), 1315-1317, 2004